FN1 and neoplasm: LOX was shown to be co-localised with fibronectin in sites of future metastasis, where it facilitated matrix remodelling, enhanced CD11b+ BMDC recruitment, and increased metastasis after being secreted from the hypoxic tumour environment of primary breast tumours.